Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 173,500 shares of Astria's common stock on May 1, 2024 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria.

The options were granted as an inducement material to four employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $9.50 which is equal to the closing price of Astria's common stock on May 1, 2024 (the "Grant Date"), and will vest over a four-year period, with 25% of shares vesting on the first anniversary of the employee's employment start date (which preceded the Grant Date) and the remaining shares vesting monthly on a ratable basis over the following 36 months, subject to the employee's continued employment with Astria on such vesting dates. The options are subject to the terms and conditions of the 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the grant.

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com , or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.

Astria Contact:

Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com

News Provided by Business Wire via QuoteMedia

ATXS:US
The Conversation (0)
Astria Therapeutics Inc.

Astria Therapeutics Inc.

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.

Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare Conference on Thursday, June 6 th at 10:00am ET in New York, NY.

A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/jeff302/atxs/1868288 . An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a healthy subject data in an encore presentation at the upcoming Eastern Allergy Conference in Palm Beach, Florida on June 1, 2024.

Jessica Best, Vice President of Medical Affairs at Astria Therapeutics, will present a poster titled, "Updated Results of a Phase 1a Trial of STAR-0215 for Hereditary Angioedema" at 9:45am EST on Saturday, June 1.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two posters at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain on June 1, 2024.

  • Dr. Marcus Maurer, M.D., Professor of Dermatology and Allergy at Charité Universitätsmedizin in Berlin, will present information on ALPHA-SOLAR, a long-term open-label trial of STAR-0215 in people living with HAE, in a poster titled "Rationale and Design of the ALPHA-SOLAR Clinical Trial of STAR-0215 for the Treatment of Hereditary Angioedema (HAE)." The poster session will take place on Saturday, June 1 at 12:00pm CEST.
  • Nikos Biris, Ph.D., Senior Director of Assay Development at Astria Therapeutics, will present information on the characterization of STAR-0310 in a poster titled "Development and Characterization of STAR-0310: a Novel OX40 Antagonistic Monoclonal Antibody." The poster session will take place on Saturday, June 1 at 12:00pm CEST.

About Astria Therapeutics:

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Questcorp Mining to Present at the Emerging Growth Conference

Questcorp Mining to Present at the Emerging Growth Conference

Questcorp Mining Inc. (CSE: QQQ,OTC:QQCMF) (OTCQB: QQCMF) (FSE: D910) (the "Company" or "Questcorp") is pleased to announce that it has been invited to Present on the Emerging Growth Conference Thursday September 25th, 2025.

Questcorp invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Finlay Minerals completes Field Work on Newly Identified Geophysical Targets on the SAY and JJB Properties

Finlay Minerals completes Field Work on Newly Identified Geophysical Targets on the SAY and JJB Properties

finlay minerals ltd. (TSXV: FYL,OTC:FYMNF) (OTCQB: FYMNF) ("Finlay" or the "Company") is pleased to announce that the results from airborne magnetic surveys conducted over the SAY and JJB properties (refer to Figure 1 ), have identified significant northwest- and northeast-trending structures. These structures resemble those found in the Toodoggone area of British Columbia which is recognized for its potential to host larger porphyry and epithermal deposits. A total of 1,900 kilometres ("km") of airborne magnetic survey data was collected over the two properties.

Follow-up groundwork at the SAY property focused on the IFT target, where a large circular magnetic anomaly, measuring 2.5 km by 2.5 km, was identified. This anomaly displays geophysical signatures similar to those observed in other copper porphyry deposits. Additionally, a second kilometre-scale target, known as Ozzy, was identified. Ozzy is located at the intersection of a northeast-trending magnetic anomaly and a northwest-trending magnetic anomaly. Further follow-up work is planned for both targets.

The SAY property was acquired in 2024, and an inaugural field program concentrated on chip sampling and mapping along the 4.3-kilometer-long SPUR Trend last summer. This effort led to the discovery of the 200 m x 200 m copper-silver mineralized AG Zone and confirmed the continuity of high-grade copper-silver mineralization at the Spur Target.  Chip sampling at the AG Zone included 9.5 metres of 0.94% Cu and 18.1 g/t Ag . (1)

The JJB property was staked in February, 2025 for its porphyry potential. Three main copper showings—Squingula, Quin, and Pat—have been identified. Squingula and Quin are located near an Eocene intrusion on the western side, and show a coincident magnetic high linked to a multi-element geochemical anomaly from limited sampling. This summer, fieldwork focused on the PAT target, one of three potential targets. This work aimed to evaluate the similarities between the high-grade copper-silver mineralization found at JJB and the SPUR/AG targets within the SAY Property.

SAY & JJB Project Highlights:

SAY 2025 Program :

JJB 2025 Program :



•       Over 1,200 line-km of airborne magnetics

•       Completion of Finlay's inaugural field program



•       Completion of property-wide LiDAR survey

•       Completion of property-wide LiDAR survey



•       Completion of satellite mineral alteration survey (PhotoSat)

•       Completion of satellite mineral alteration survey (PhotoSat)



•       84 rock samples collected

•       700 line-km of airborne magnetics



•       307 soil samples collected

•       18 rock samples collected



•       275 biogeochemistry samples collected

•       35 soil and talus samples collected

Processing of the LiDAR and satellite mineral alteration data is on-going.  All field samples have been submitted to the laboratory for analysis with results pending.

Situated in the underexplored Bear Lake corridor, the SAY and JJB projects are part of a 135-kilometre geological corridor that includes American Eagle Gold's NAK project, as well as Amarc Resources and Boliden Mineral Canada's DUKE copper-molybdenum-silver-gold prospects.

PIL and ATTY Project Updates:

Exploration work at the PIL and ATTY Toodoggone projects is on-going and anticipated to be completed within the next two weeks with continued induced polarization geophysical surveys. The PIL and ATTY work is fully funded by Freeport-McMoRan Mineral Properties Canada Inc. under their respective Earn-In Agreements (2) with Finlay acting as the operator.

References:

  1. Finlay news release NR13-24 dated November 20, 2024 entitled: " Finlay Minerals samples 1.17% Cu and 103.5 g/t Ag across 21.7 meters of a Continuous Chip Sample on the SAY Property ".

  2. Finlay news releases NR03-25 dated April 17, 2025 entitled: " Finlay Minerals Enters into Earn-In Agreements with Freeport for its PIL & ATTY Properties " and NR 05-25 dated May 2, 2025 and entitled: " Finlay Minerals Receives TSX Venture Exchange Approval for PIL Earn-In Agreement. "

Qualified Person:

Wade Barnes , P. Geo. and Vice President, Exploration for Finlay Minerals and a qualified person as defined by National Instrument 43-101, has approved the technical content of this news release.

About finlay minerals ltd.

Finlay is a TSXV company focused on exploration for base and precious metal deposits through the advancement of its ATTY, PIL, JJB, SAY and Silver Hope Properties; these properties host copper-gold porphyry and gold-silver epithermal targets within different porphyry districts of northern and central BC. Each property is located in areas of recent development and porphyry discoveries with the advantage of hosting the potential for new discoveries.

Finlay trades under the symbol "FYL" on the TSXV and under the symbol "FYMNF" on the OTCQB. For further information and details, please visit the Company's website at www.finlayminerals.com

On behalf of the Board of Directors,

Robert F. Brown ,
Executive Chairman of the Board

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of applicable Canadian securities legislation. All statements in this news release that address events or developments that we expect to occur in the future are forward-looking statements.  Forward-looking statements are statements that are not historical facts and are generally, although not always, identified by words such as "expect", "plan", "anticipate", "project", "target", "potential", "schedule", "forecast", "budget", "estimate", "intend" or "believe" and similar expressions or their negative connotations, or that events or conditions "will", "would", "may", "could", "should" or "might" occur. All such forward-looking statements are based on the opinions and estimates of management as of the date such statements are made. Forward-looking statements in this news release include statements regarding, among others, the exploration plans for the Properties. Although Finlay believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploration successes, and continued availability of capital and financing and general economic, market or business conditions. These forward-looking statements are based on a number of assumptions including, among other things, assumptions regarding general business and economic conditions, the timing and receipt of regulatory and governmental approvals, the ability of Finlay and other parties to satisfy stock exchange and other regulatory requirements in a timely manner, the availability of financing for Finlay's proposed transactions and programs on reasonable terms, and the ability of third-party service providers to deliver services in a timely manner. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements, and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein. Finlay does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future or otherwise, except as required by applicable law.

SOURCE finlay minerals ltd.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2025/22/c1184.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Copper Quest Acquires the Nekash Copper-Gold Porphyry Project in Idaho, USA

Copper Quest Acquires the Nekash Copper-Gold Porphyry Project in Idaho, USA

// Not for distribution to the United States newswire services or for dissemination in the United States //

Copper Quest Exploration Inc. (CSE: CQX; OTCQB: IMIMF; FRA: 3MX) (" Copper Quest " or the " Company ") is pleased to announce that it has closed the previously announced acquisition of the Nekash Copper-Gold Porphyry Project (" Nekash " or the " Project ") located in Lemhi County, Idaho, United States. This acquisition marks an important milestone in the Company's strategy to build a portfolio of highly prospective copper assets across North America.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Silver47 Announces Grant of Stock Options and Restricted Share Units

Silver47 Announces Grant of Stock Options and Restricted Share Units

Silver47 Exploration Corp. (TSXV: AGA,OTC:AAGAF) (OTCQB: AAGAF) ("Silver47" or the "Company") announces that it has granted an aggregate of 5,300,000 incentive stock options (the "Options") and 180,000 Restricted Share Units ("RSUs") to certain directors, officers and consultants of the Company in accordance with the Company's omnibus security based compensation plan. The Options are exercisable at a price of C$0.78 and will expire five years from the date of grant and will vest on the date of grant. The RSUs will vest over two years starting on the first anniversary of grant.

About Silver47 Exploration

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News